Form 4: UroGen Pharma Director Acquires 10,000 Stock Options
SEC Form 4 Filing
Director James A. Robinson Jr. acquired 10,000 stock options in UroGen Pharma Ltd. on August 6, 2024.
Summary
- On August 6, 2024, James A. Robinson Jr., a director of UroGen Pharma Ltd., acquired 10,000 stock options.
- The exercise price of these options is $15.16.
- The options vest in equal quarterly installments over one year, contingent upon the director's continuous service.
- The options expire on August 6, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting of the stock options is contingent upon the director's continuous service, suggesting a commitment to the company's ongoing success.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of management with those of shareholders.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of transaction: Director acquired 10,000 stock options. |
| 08/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.